Kristen Stevenson

Title: Kristen Stevenson: Innovator in Myelodysplastic Syndrome Research

Introduction

Kristen Stevenson is a notable inventor based in Waltham, MA (US). She has made significant contributions to the field of medical research, particularly in the area of myelodysplastic syndrome. With a total of 2 patents, her work focuses on improving treatment outcomes for patients suffering from this condition.

Latest Patents

One of her latest patents is titled "Methods for determining response to a hypomethylating agent." This patent discloses methods for predicting a subject's response to treatment with a hypomethylating agent, utilizing samples obtained from the subject. The methods aim to select suitable candidates for treatment and measure their response to therapy, as well as monitor disease progression or regression. Another significant patent is "Mutation signatures for predicting the survivability of myelodysplastic syndrome subjects." This patent highlights that somatic non-silent mutations on selected biomarkers serve as reliable indicators for the overall survival of patients with myelodysplastic syndrome.

Career Highlights

Throughout her career, Kristen has worked with prestigious institutions such as Dana-Farber Cancer Institute Inc. and Brigham and Women's Hospital. Her research has been instrumental in advancing the understanding and treatment of myelodysplastic syndrome.

Collaborations

Kristen has collaborated with esteemed colleagues, including Rafael Bejar and Benjamin L. Ebert. These partnerships have further enriched her research and contributed to the development of innovative treatment methodologies.

Conclusion

Kristen Stevenson is a pioneering inventor whose work in myelodysplastic syndrome research has the potential to significantly impact patient care. Her patents reflect her commitment to advancing medical science and improving treatment outcomes for those affected by this challenging condition.